Nan L Li

20120162438, Jun 28, 2012

Sep 7, 2010

13/394261

Nitish Thakor - Clarksville MD, US
Abhishek Rege - Baltimore MD, US
Nan Li - Baltimore MD, US
Kartikeya Murari - Silver Spring MD, US

The John Hopkins University - Baltimore MD

H04N 7/18

348161, 348E07085

A system for multimodal laser speckle imaging may include a first light source positioned to emit laser light toward a target, a second light source positioned to emit light toward the target, a camera positioned to receive light scattered from the target, and a processor. The processor may be programmed to receive from the at least one camera at least one image of the target as illuminated by the laser, obtain a laser speckle contrast image of the target from the at least one image of the target as illuminated by the laser, receive from the at least one camera at least one image of the target as illuminated by the second light source, divide the laser speckle contrast image into subparts, and divide the at least one image of the target as illuminated by the second light source into identical subparts, determine whether each subpart includes a feature of a certain type by combining each subpart of the laser speckle contrast image with the at least one image of the target as illuminated by the second light source and comparing the combination with one or more criteria, and outputting the location and type of features detected in a subpart of the images.

20210371542, Dec 2, 2021

Nov 7, 2018

16/762459

- Bethesda MD, US
Nan Li - Laurel MD, US
Dan Li - Bethesda MD, US

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

C07K 16/30
C07K 14/715
C07K 14/71
C07K 14/705
C07K 14/725
A61K 35/17
A61P 35/00

Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8α hinge region, a CD8α transmembrane region, a 4-1BB co-stimulatory domain and a CD3ζ signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

20210292428, Sep 23, 2021

Aug 6, 2019

17/266419

- Bethesda MD, US
Nan Li - Laurel MD, US
Bryan D. Fleming - Bethesda MD, US

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

C07K 16/30
C07K 14/725
A61K 47/68
G01N 33/574
C12N 15/86
A61P 35/00

Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

20200216558, Jul 9, 2020

Jul 20, 2017

16/322712

- Bethesda US, US
Nan Li - Laurel MD, US
Dimiter S. Dimitrov - Pittsburgh PA, US

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

C07K 16/30
C07K 16/28
C07K 7/08
A61K 47/69
A61K 47/64
A61P 35/00

A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2-positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form of exotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2-specific CARs potently killed GPC2-positive neuroblastoma cells in a dose-dependent manner.

20160113504, Apr 28, 2016

Oct 9, 2015

14/879260

- Baltimore MD, US
Nitish THAKOR - Clarksville MD, US
Kartikeya MURARI - Calgary, CA
Nan Li - Arlington MA, US

A61B 5/00
A61B 5/026

A system for multimodal laser speckle imaging may include a first light source positioned to emit laser light toward a target, a second light source positioned to emit light toward the target, a camera positioned to receive light scattered from the target, and a processor. The processor may be programmed to receive from the at least one camera at least one image of the target as illuminated by the laser, obtain a laser speckle contrast image of the target from the at least one image of the target as illuminated by the laser, receive from the at least one camera at least one image of the target as illuminated by the second light source, divide the laser speckle contrast image into subparts, and divide the at least one image of the target as illuminated by the second light source into identical subparts, determine whether each subpart includes a feature of a certain type by combining each subpart of the laser speckle contrast image with the at least one image of the target as illuminated by the second light source and comparing the combination with one or more criteria, and out-putting the location and type of features detected in a subpart of the images.